Has Danielle Wyant received payments from drug or device companies?

Yes. Drug and device makers reported $8,682 in general payments to Danielle Wyant across 506 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Danielle Wyant did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Danielle Wyant come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Danielle Wyant

Neurology with Special Qualifications in Child Neurology · Durham, NCNPI 1760651905

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.5% of the total across 506 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 60 manufacturers reported payments, led by UCB, Inc. at 26.0% of the total.

$8,682in general payments, 2019–2025

Across 506 payments — averaging $17.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

UCB, Inc.$2K
Neurelis, Inc.$456
Jazz Pharmaceuticals Inc.$375
Livanova USA, Inc.$374
Eisai Inc.$358
Sunovion Pharmaceuticals Inc.$355
plus $4K from 54 others

What the payments were for

Speaking & faculty fees$441%
Food & beverage$8,63899%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
UCB, Inc.	103	$2,261
Neurelis, Inc.	24	$456
Jazz Pharmaceuticals Inc.	16	$375
Livanova USA, Inc.	15	$374
Eisai Inc.	21	$358
Sunovion Pharmaceuticals Inc.	27	$355
AbbVie	18	$337
AstraZeneca	14	$304
Avadel CNS Pharmaceuticals, LLC	13	$277
Sumitomo Pharma America, Inc.	14	$243
Ironshore Pharmaceuticals Inc.	12	$224
Aquestive Therapeutics, Inc.	13	$217
Corium, LLC	10	$209
Aucta Pharmaceuticals, Inc.	10	$170
Supernus Pharmaceuticals, Inc.	69	$130
Harmony Biosciences LLC	5	$127
Merz Pharmaceuticals, LLC	4	$117
Mallinckrodt Enterprises LLC	6	$109
Sanofi	6	$109
Amneal Pharmaceuticals LLC	6	$106
SK Life Science, Inc.	4	$105
Biomarin Pharmaceutical Inc.	4	$103
Grifols USA, LLC	4	$98
Springworks Therapeutics, Inc.	4	$88
Catalyst Pharmaceuticals, Inc.	4	$85
Aprecia Pharmaceuticals, LLC	5	$82
Greenwich Biosciences, Inc.	4	$71
Avanir Pharmaceuticals, Inc.	4	$71
Ipsen Biopharmaceuticals, Inc	4	$65
Immedica Pharma US, Inc.	3	$64
Adamas Pharmaceuticals, Inc.	4	$58
Tris Pharma Inc	4	$55
Argenx US, Inc.	2	$52
Teva Pharmaceuticals USA, Inc.	3	$51
Neos Therapeutics, LP	4	$48
Biohaven Pharmaceutical Holding Company Ltd.	3	$44
Acorda Therapeutics, Inc	3	$44
Biogen	2	$43
Azurity Pharmaceuticals, Inc.	2	$42
Lundbeck LLC	2	$38
Axsome Therapeutics, Inc.	2	$35
CSL Behring	2	$30
Rhodes Pharmaceuticals L.p.	2	$29
Novartis	2	$28
Promius Pharma LLC	2	$28
Neurocrine Biosciences, Inc.	2	$26
Upsher-smith Laboratories LLC	1	$25
Merz North America, Inc.	1	$24
Intrabio Inc	1	$22
Bausch Health US, LLC	1	$21
Ultragenyx Pharmaceutical Inc.	1	$19
Johnson & Johnson	1	$19
Vertical Pharmaceuticals, LLC	1	$19
Siemens Medical Solutions USA, Inc.	1	$19
Kedrion Biopharma, Inc.	1	$19
Collegium Pharmaceutical, Inc.	1	$18
Takeda Pharmaceuticals U.S.A., Inc.	1	$18
Avion Pharmaceuticals	1	$17
Mallinckrodt Hospital Products Inc.	1	$16
Arbor Pharmaceuticals, Inc.	1	$16

How this compares

$8,682 in reported general payments places this provider in the 80th percentile of 46 neurology with special qualifications in child neurology providers in North Carolina.

See all neurology with special qualifications in child neurology providers in North Carolina →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Levetiracetam	12	$334

Paid to pharmacies, not to this prescriber.

Other neurology with special qualifications in child neurology in Durham

Natalie KatzDurham$60K
Kevin RathkeDurham$39K
Dmitry TchapyjnikovDurham$919
Brooke AsemotaDurham$241
Sujay KansagraDurham$226
Monica LemmonDurham$1
Shana WallaceCharlotte$58K
Robert NahouraiiConcord$37K
Shalaka IndulkarFayetteville$19K
Khaled JreisatWilmington$13K

See the full list for North Carolina →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →